The goal of the proposed studies is to improve the therapeutic effectiveness of monoclonal antibodies in the treatment of lymphoma. Our previous studies using unmodified antibodies against a normal T cell differentiation antigen to treat murine T cell lymphoma demonstrated anti-tumor activity. However, limitations of this approach suggested the use of antibodies conjugated with a radionuclide to improve therapeutic effectiveness. Preliminary studies using I-131-labeled monoclonal anti-Thy 1.1 antibodies have met with success in eliminating large tumor masses. We now propose to evaluate ways to improve the effectiveness of this approach by increasing the amount of radiation that can be targeted to a solid tumor mass as compared to critical normal organs. We will determine whether localization of radiolabeled antibody at tumor sites can be improved by using IL-2 to increase antibody uptake. We will also determine whether the maximum radiation dose that can be delivered to tumor can be increased by using radioprotectors to reduce radiation toxicity to normal organs and whether the biodistribution of the antibody targeted radionuclide can be improved by utilizing a new iodination method. The methods developed in these studies with large tumor masses will then be applied in efforts to eliminate disseminated transplanted and spontaneous lymphoma. In these studies, the effectiveness of antibodies specific for malignant as compared to normal T cells will be assessed. The success of these techniques in improving the therapeutic efficacy of radiolabeled monoclonal antibodies in this murine model would provide the basis for the use of these new approaches in clinical trials with patients with lymphoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA026386-11
Application #
3482061
Study Section
Experimental Immunology Study Section (EI)
Project Start
1979-07-01
Project End
1992-12-31
Budget Start
1990-01-01
Budget End
1990-12-31
Support Year
11
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Appelbaum, F R (1997) Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin Oncol 24:114-23
Appelbaum, F R (1996) The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer. CA Cancer J Clin 46:142-64
van der Jagt, R H; Badger, C C; Appelbaum, F R et al. (1992) Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res 52:89-94
Schultz, K R; Badger, C C; Dombi, G W et al. (1992) Effect of interleukin-2 on biodistribution of monoclonal antibody in tumor and normal tissues in mice bearing SL-2 thymoma. J Natl Cancer Inst 84:109-13
Badger, C C; Rasey, J; Nourigat, C et al. (1991) WR2721 protection of bone marrow in 131I-labeled antibody therapy. Radiat Res 128:320-4
Badger, C C; Davis, J; Nourigat, C et al. (1991) Biodistribution and dosimetry following infusion of antibodies labeled with large amounts of 131I. Cancer Res 51:5921-8
Ali, S A; Warren, S D; Richter, K Y et al. (1990) Improving the tumor retention of radioiodinated antibody: aryl carbohydrate adducts. Cancer Res 50:783s-788s
Bianco, J A; Appelbaum, F R (1990) Biotherapy after marrow transplantation and the use of hematopoietic growth factors. Curr Opin Oncol 2:289-96
Ali, S A; Eary, J F; Warren, S D et al. (1988) Synthesis and radioiodination of tyramine cellobiose for labeling monoclonal antibodies. Int J Rad Appl Instrum B 15:557-61
Anasetti, C; Martin, P J; Morishita, Y et al. (1987) Human large granular lymphocytes express high affinity receptors for murine monoclonal antibodies of the IgG3 subclass. J Immunol 138:2979-81

Showing the most recent 10 out of 13 publications